应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
UPB UpStream Bio Inc.
交易中 12-19 13:14:49 EST
15.44
-0.67
-4.16%
最高
17.86
最低
14.99
成交量
16.84万
今开
16.24
昨收
16.11
日振幅
17.82%
总市值
8.28亿
流通市值
1.93亿
总股本
5,360万
成交额
261.40万
换手率
1.35%
流通股本
1,250万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
资讯
新帖
简况
单月超6亿美元,医药企业IPO规模重返疫情前水平
财通社 · 11-25
单月超6亿美元,医药企业IPO规模重返疫情前水平
更新版 2-高盛支持的药物开发商 Septerna 在美国首次公开募股中目标估值 7.43 亿美元
路透中文 · 10-24
更新版 2-高盛支持的药物开发商 Septerna 在美国首次公开募股中目标估值 7.43 亿美元
加载更多
公司概况
公司名称:
UpStream Bio Inc.
所属市场:
NASDAQ
上市日期:
--
主营业务:
Upstream Bio, Inc.于2021年4月在特拉华州注册成立。他们是一家临床阶段的生物技术公司,开发炎症性疾病的治疗方法,最初专注于严重的呼吸系统疾病。他们正在开发verekitug,这是目前临床开发中唯一已知的拮抗剂,靶向胸腺间质淋巴细胞生成素(“TSLP”)受体,TSLP是一种细胞因子,是临床验证的炎症反应驱动因素,位于影响各种免疫介导疾病的多个信号级联的上游。迄今为止的临床前和临床数据表明,verekitug对TSLP受体具有高度有效的抑制作用,这将转化为差异化的产品特征,包括改善临床结果、大幅延长给药间隔和治疗广泛患者的潜力。他们经验丰富的团队致力于最大限度地发挥verekitug的独特属性,以满足当今护理标准无法满足的患者的大量未满足需求。
发行价格:
--
{"stockData":{"symbol":"UPB","market":"US","secType":"STK","nameCN":"UpStream Bio Inc.","latestPrice":15.44,"timestamp":1734632088052,"preClose":16.11,"halted":0,"volume":168394,"delay":0,"floatShares":12500000,"shares":53596601,"eps":-24.29691,"marketStatus":"交易中","marketStatusCode":2,"change":-0.67,"latestTime":"12-19 13:14:49 EST","open":16.24,"high":17.86,"low":14.99,"amount":2614015.42474,"amplitude":0.17815,"askPrice":15.49,"askSize":711,"bidPrice":15.39,"bidSize":380,"shortable":0,"etf":0,"ttmEps":-24.29691,"exchange":"NASDAQ","tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1734642000000},"adr":0,"listingDate":1728619200000,"adjPreClose":16.11,"preHourTrading":{"tag":"盘前","latestPrice":17,"preClose":16.11,"latestTime":"08:54 EST","volume":164,"amount":2786.9999279999997,"timestamp":1734616483097},"postHourTrading":{"tag":"盘后","latestPrice":16.42,"preClose":16.11,"latestTime":"19:41 EST","volume":2325,"amount":37247.76,"timestamp":1734568876648},"volumeRatio":0.673661},"requestUrl":"/m/hq/s/UPB","defaultTab":"news","newsList":[{"id":"2486705257","title":"单月超6亿美元,医药企业IPO规模重返疫情前水平","url":"https://stock-news.laohu8.com/highlight/detail?id=2486705257","media":"财通社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486705257?lang=zh_cn&edition=full","pubTime":"2024-11-25 17:34","pubTimestamp":1732527240,"startTime":"0","endTime":"0","summary":"今年以来,生物医药领域已经有30家公司IPO上市,累计融资规模超40.49亿美元,其中不乏CG Oncology、Kyverna Therapeutics等IPO规模超3亿美元的公司。在多肽类PTH1R激动剂领域,阿斯利康以总价18亿美元收购AmolytPharma,获得了处于临床3期的PTH1R激动剂eneboparatide,目前该疗法已经获得了FDA快速通道认定,另一家药企AscendisPharma的Yorvipath获得FDA批准上市,用于治疗成人慢性甲状旁腺功能减退。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2024-11-25/doc-incxhqmk8147031.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["TSLP","BK4082","NQmain","GLYC","AVTE","SQQQ","BK4020","SEPN","TQQQ","BK4599","CAMP","OMGA",".IXIC","BK4139","BDMD","SYRS","BK4561","BK4539","APGE","QID","ASO","PSQ","BK4200","QLD","UPB","MNQmain","GPCR","BK4007"],"gpt_icon":1},{"id":"2477636551","title":"更新版 2-高盛支持的药物开发商 Septerna 在美国首次公开募股中目标估值 7.43 亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2477636551","media":"路透中文","labels":["shareholding","productRelease","event"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477636551?lang=zh_cn&edition=full","pubTime":"2024-10-24 20:08","pubTimestamp":1729771713,"startTime":"0","endTime":"0","summary":"更新版 2-高盛支持的药物开发商 Septerna 在美国首次公开募股中目标估值 7.43 亿美元第 3-5 段补充了生物技术行业的背景,第 6-7 段补充了 Septerna 的主要药物。路透10月24日 - 高盛支持的药物开发商赛普特纳公司周四表示,该公司将在美国进行规模更大的首次公开募股,寻求获得 7.431 亿美元的估值,这表明投资者对这一资本密集型行业的乐观情绪。高盛持有 Septerna 5.4% 的股份,该公司目前的目标是通过出售近 1530 万股每股 18 美元的股票筹集 2.75 亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241024:nL4S3M01LN:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,productRelease,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2237443465.HKD","BK4588","IE00BSNM7G36.USD","LU1791807156.HKD","LU2237438978.USD","LU2237443895.HKD","BIOA","BK4552","IE0002270589.USD","LU1668664300.SGD","BK4127","BK4550","LU2237443978.SGD","LU2237443382.USD","BK4585","IE0034235188.USD","IE00B19Z3B42.SGD","IE00B19Z3581.USD","LU2237443549.SGD","UPB","LU0106831901.USD","BCAX","MBX","BK4533","IE0004091025.USD","BK4007","IE0004086264.USD","BK4504","BK4139","LU2237443622.USD","IE00BFXG1179.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.upstreambio.com","stockEarnings":[{"period":"1week","weight":-0.2514},{"period":"1month","weight":-0.3223},{"period":"3month","weight":-0.0524},{"period":"ytd","weight":-0.0524}],"compareEarnings":[{"period":"1week","weight":-0.0349},{"period":"1month","weight":-0.0032},{"period":"3month","weight":0.0268},{"period":"6month","weight":0.0767},{"period":"1year","weight":0.2347},{"period":"ytd","weight":0.2335}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Upstream Bio, Inc.于2021年4月在特拉华州注册成立。他们是一家临床阶段的生物技术公司,开发炎症性疾病的治疗方法,最初专注于严重的呼吸系统疾病。他们正在开发verekitug,这是目前临床开发中唯一已知的拮抗剂,靶向胸腺间质淋巴细胞生成素(“TSLP”)受体,TSLP是一种细胞因子,是临床验证的炎症反应驱动因素,位于影响各种免疫介导疾病的多个信号级联的上游。迄今为止的临床前和临床数据表明,verekitug对TSLP受体具有高度有效的抑制作用,这将转化为差异化的产品特征,包括改善临床结果、大幅延长给药间隔和治疗广泛患者的潜力。他们经验丰富的团队致力于最大限度地发挥verekitug的独特属性,以满足当今护理标准无法满足的患者的大量未满足需求。","exchange":"NASDAQ","name":"UpStream Bio Inc.","nameEN":"UpStream Bio Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"UpStream Bio Inc.(UPB)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供UpStream Bio Inc.(UPB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"UpStream Bio Inc.,UPB,UpStream Bio Inc.股票,UpStream Bio Inc.股票老虎,UpStream Bio Inc.股票老虎国际,UpStream Bio Inc.行情,UpStream Bio Inc.股票行情,UpStream Bio Inc.股价,UpStream Bio Inc.股市,UpStream Bio Inc.股票价格,UpStream Bio Inc.股票交易,UpStream Bio Inc.股票购买,UpStream Bio Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"UpStream Bio Inc.(UPB)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供UpStream Bio Inc.(UPB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}